{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:04:25Z","timestamp":1793261065666,"version":"4.5.0"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,9,6]]},"DOI":"10.1001\/jama.2022.14578","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:37:05Z","timestamp":1662464225000},"page":"872","source":"Crossref","is-referenced-by-count":257,"title":["Diagnosis and Treatment of Myelodysplastic Syndromes"],"prefix":"10.1001","volume":"328","author":[{"given":"Mikkael A.","family":"Sekeres","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"20","key":"jrv220014r1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"jrv220014r2","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes.","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"1","key":"jrv220014r4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"6","key":"jrv220014r5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia.","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin Oncol"},{"issue":"17","key":"jrv220014r6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2017-02-767731","article-title":"Origins of myelodysplastic syndromes after aplastic anemia.","volume":"130","author":"Negoro","year":"2017","journal-title":"Blood"},{"issue":"5","key":"jrv220014r7","doi-asserted-by":"publisher","first-page":"E280","DOI":"10.1002\/ajh.v91.5","article-title":"Autoimmune diseases and myelodysplastic syndromes.","volume":"91","author":"Komrokji","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"jrv220014r8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1200\/JCO.2010.31.3080","article-title":"Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors.","volume":"29","author":"Iwanaga","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"jrv220014r9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in ddx41 in myeloid neoplasms.","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"},{"issue":"3","key":"jrv220014r10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/BF02982044","article-title":"Biological significance of proliferation, apoptosis, cytokines, and monocyte\/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome.","volume":"75","author":"Allampallam","year":"2002","journal-title":"Int J Hematol"},{"issue":"8","key":"jrv220014r11","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"jrv220014r12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.","volume":"25","author":"Woll","year":"2014","journal-title":"Cancer Cell"},{"issue":"8","key":"jrv220014r13","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2007-03-079368","article-title":"The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.","volume":"110","author":"Nilsson","year":"2007","journal-title":"Blood"},{"issue":"12","key":"jrv220014r14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1182\/blood-2016-10-696062","article-title":"Stem and progenitor cell alterations in myelodysplastic syndromes.","volume":"129","author":"Shastri","year":"2017","journal-title":"Blood"},{"issue":"11","key":"jrv220014r15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMc1500684","article-title":"Clonal hematopoiesis and blood-cancer risk.","volume":"372","author":"Genovese","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"jrv220014r16","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes.","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"jrv220014r17","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"jrv220014r18","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/jnci\/djn349","article-title":"Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.","volume":"100","author":"Sekeres","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"jrv220014r19","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.3324\/haematol.2012.063420","article-title":"Infections in myelodysplastic syndromes.","volume":"97","author":"Toma","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"jrv220014r20","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/bloodadvances.2021004755","article-title":"A geno-clinical decision model for the diagnosis of myelodysplastic syndromes.","volume":"5","author":"Radakovich","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"jrv220014r21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2141.1986.tb07550.x","article-title":"Diagnostic significance of detecting pseudo-Pelger-Hu\u00ebt anomalies and micro-megakaryocytes in myelodysplastic syndrome.","volume":"63","author":"Kuriyama","year":"1986","journal-title":"Br J Haematol"},{"issue":"21","key":"jrv220014r22","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"issue":"7","key":"jrv220014r23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms.","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"jrv220014r24","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia.","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"3","key":"jrv220014r25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"4","key":"jrv220014r26","first-page":"358","article-title":"Prognostic factors and scoring systems in myelodysplastic syndromes.","volume":"83","author":"Sanz","year":"1998","journal-title":"Haematologica"},{"issue":"6","key":"jrv220014r27","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"7","key":"jrv220014r28","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","article-title":"Time-dependent changes in mortality and transformation risk in MDS.","volume":"128","author":"Pfeilst\u00f6cker","year":"2016","journal-title":"Blood"},{"issue":"11","key":"jrv220014r29","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes.","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"33","key":"jrv220014r30","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes.","volume":"39","author":"Nazha","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv220014r31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/hematology.2019000040","article-title":"Lowering the boom on lower-risk myelodysplastic syndromes.","volume":"2019","author":"Sekeres","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"jrv220014r32","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"16","key":"jrv220014r33","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.","volume":"29","author":"Naqvi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv220014r34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/bjh.2008.142.issue-3","article-title":"Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.","volume":"142","author":"Gabrilove","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"jrv220014r35","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"jrv220014r36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/bjh.2007.137.issue-2","article-title":"Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.","volume":"137","author":"Golshayan","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"jrv220014r37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u00df superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"issue":"14","key":"jrv220014r38","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q.","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"12","key":"jrv220014r39","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/cncr.v120.12","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"jrv220014r40","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"issue":"3","key":"jrv220014r41","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"issue":"7","key":"jrv220014r42","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3324\/haematol.2012.083345","article-title":"A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.","volume":"99","author":"Komrokji","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"jrv220014r43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care\u2013SAKK 33\/99.","volume":"29","author":"Passweg","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv220014r44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1634\/theoncologist.2017-0215","article-title":"Azacitidine in lower-risk myelodysplastic syndromes: a meta-analysis of data from prospective studies.","volume":"23","author":"Komrokji","year":"2018","journal-title":"Oncologist"},{"issue":"6","key":"jrv220014r45","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study.","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"3","key":"jrv220014r46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"24","key":"jrv220014r47","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase ii study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117.","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"jrv220014r48","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905.","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"jrv220014r49","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv220014r50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.amjmed.2005.08.027","article-title":"Impact of anemia on mortality, cognition, and function in community-dwelling elderly.","volume":"119","author":"Denny","year":"2006","journal-title":"Am J Med"},{"issue":"10","key":"jrv220014r51","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1182\/blood-2005-10-4308","article-title":"Impact of anemia on hospitalization and mortality in older adults.","volume":"107","author":"Culleton","year":"2006","journal-title":"Blood"},{"issue":"6","key":"jrv220014r52","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.","volume":"120","author":"Hellstr\u00f6m-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"jrv220014r53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood.V108.11.521.521","article-title":"Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. American Society of Hematology Annual Meeting Abstract.","volume":"108","author":"J\u00e4dersten","year":"2006","journal-title":"Blood"},{"issue":"2","key":"jrv220014r54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"2","key":"jrv220014r55","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes.","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv220014r56","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/leu.2010.105","article-title":"WHO-defined \u2018myelodysplastic syndrome with isolated del(5q)\u2019 in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.","volume":"24","author":"Patnaik","year":"2010","journal-title":"Leukemia"},{"issue":"7176","key":"jrv220014r57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"issue":"7559","key":"jrv220014r58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS.","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"issue":"36","key":"jrv220014r59","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1200\/JCO.2007.15.5770","article-title":"Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.","volume":"26","author":"Sekeres","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"jrv220014r60","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/(ISSN)1097-0142","article-title":"The incidence and impact of thrombocytopenia in myelodysplastic syndromes.","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"jrv220014r61","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability.","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"jrv220014r62","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/10428194.2020.1751841","article-title":"A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.","volume":"61","author":"Duong","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"jrv220014r63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.seminoncol.2011.11.011","article-title":"p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.","volume":"39","author":"Saunthararajah","year":"2012","journal-title":"Semin Oncol"},{"issue":"13","key":"jrv220014r64","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN.","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"3","key":"jrv220014r65","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/j.seminhematol.2017.06.001","article-title":"Optimizing the use of hypomethylating agents in myelodysplastic syndromes: selecting the candidate, predicting the response, and enhancing the activity.","volume":"54","author":"Madanat","year":"2017","journal-title":"Semin Hematol"},{"issue":"7","key":"jrv220014r66","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML.","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"jrv220014r67","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/bjh.2016.175.issue-5","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"jrv220014r68","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/cncr.v123.6","article-title":"Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.","volume":"123","author":"Garcia-Manero","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"jrv220014r69","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol"},{"issue":"15","key":"jrv220014r70","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase ib\/ii study.","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"24","key":"jrv220014r71","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv220014r72","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"21","key":"jrv220014r73","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"issue":"30","key":"jrv220014r74","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome.","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv220014r75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","article-title":"Comparison of patient age groups in transplantation for myelodysplastic syndrome: the Medicare Coverage With Evidence Development Study.","volume":"6","author":"Atallah","year":"2020","journal-title":"JAMA Oncol"},{"key":"jrv220014r3","unstructured":"Surveillance Research Program, National Cancer Institute. All cancer sites combined: recent trends in SEER age-adjusted incidence rates, 2000-2019 by sex, delay-adjusted SEER incidence rate, all races, all ages. Accessed June 22, 2022. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2795886\/jama_sekeres_2022_rv_220014_1662052709.74464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:37:09Z","timestamp":1662464229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2795886"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,6]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.14578","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,6]]}}}